Rheumatism arthritis (RA) is a chronic, systemic, self-immunological disease, mainly manifested in arthritis and ecstasy. There are limitations in controlling the progress of diseases, such as traditional treatments such as inflammation drugs and rheumatizers to improve conditions. The presence of biological agents, on the other hand, has many benefits for persons with rheumatism arthritis.
i. Precision targeting treatment
The greatest advantage of single cloned antibodies or integrated proteins produced by genetic engineering is the ability to target precisely key cell factors or molecular targets in the disease-related mechanisms. For example, the tumour cause of death – alpha (TNF-α) constrictor is a more widely applied category of biological agents. TNF-α plays a key inflammation role during the onset of rheumatism arthritis, which activates inflammatory cells, induces the release of inflammatory media and leads to the inflammation and increase of the joints. TNF-α resistance agents are able to combine TNF-α in a specific way, disrupting their biological activity and thus effectively reducing arthritis. This precise target-oriented treatment, which is like a precision-guided missile, directly acts as a critical component of the disease, and is more rapid in alleviating the symptoms of corrosive pain, morning rigidities and so forth than traditional medicines.
II. Quick start
For people with rheumatism arthritis, the pain at the onset of the disease and the restricted function of the joint seriously affect the quality of life. Rapid effects of biological agents give hope to patients. In general, a significant improvement in the symptoms is felt within days to weeks after the introduction of biological agents. Compared to the traditional Rheumatoids (DMARDs), DMARDs often take months to achieve better treatment. For example, in a clinical study, the pain and swelling of the joints decreased significantly after two weeks of treatment for patients who had been treated with a single anti-Adam (a biological formulation), while the symptoms of patients who had used traditional drugs, such as aminos, had not improved significantly over the same period. This quick-impact characteristic allows patients to return to normal life and work more quickly and reduces the physical and mental suffering of the disease.
III. Improving joint functions
If not effectively controlled, rheumatism arthritis can gradually lead to joint malformations and loss of function. By inhibiting inflammatory response, biological agents not only reduce the pain and swelling of the joint, but also effectively slow down the destruction of the joint structure and improve its function. The long-term use of biological agents reduces the incidence of joint erosion and narrow joint gaps. Studies have shown that joint function indicators such as fine hand movements and walking capacity can be better maintained and improved after treatment for people with rheumatism-like arthritis treated with biological agents. For example, after a period of treatment with biological agents, a hand that could not hold a fist because of joint pain can gradually return to normal boxing functions, which is of great importance for improving the ability of the patient to provide for himself.
IV. Options for individualized treatment
Biological agents are of a variety of types, with slightly different impact targets and mechanisms, which provide more individualized treatment options for clinicians depending on the patient ‘ s circumstances. For example, for patients who have a poor or intolerant reaction to TNF-α, biological agents can be selected for receptor-6 (IL-6). The degree of disease activity, complications and drug resistance vary from one patient to another, and the diversity of biological agents allows doctors to develop treatment programmes with greater flexibility to achieve optimal treatment. At the same time, as medical research continues, new biological agents are being developed and placed on the market, providing more treatment possibilities for patients.
Reduction of sugar cortex hormone use
Sugar cortex hormones are a common drug in the treatment of rheumatism arthritis, but their long-term intensive use can lead to many adverse effects, such as osteoporosis, hypertension and diabetes. Application of biological agents can reduce the use of sugar cortex hormones to some extent. Because biological agents can effectively control inflammation, in joint treatment programmes, doctors can gradually reduce the dose of sugar cortex hormones based on the patient ‘ s condition, thereby reducing the risk of side effects due to sugar cortex hormones. This is very useful for long-term health management of patients.
VI. Improving the quality of life and mental state of patients
Patients of rheumatism arthritis suffer from chronic illness and often suffer from psychological conditions such as anxiety and depression. Good treatment of biological agents improves the physical condition of patients and reduces pain and joint functional impairments, thereby significantly improving their quality of life. Patients are more free to carry out their daily activities, such as dressing, washing, walking, etc., which helps to increase their self-confidence and improve their psychological state. Moreover, when a patient sees his or her condition under effective control, the dependence on treatment also increases, creating a virtuous cycle conducive to long-term stable control of the disease.
The use of biological agents for rheumatism arthritis has numerous benefits, ranging from precision treatment to rapid improvement of symptoms, protection of joint function, provision of individualization programmes, to the reduction of side effects of other drugs and improvement of the quality of life of patients, which demonstrate the important value of biological agents in the field of rheumatological arthritis treatment. Of course, the potential risks and costs of biological agents, among other factors, need to be fully taken into account when using them, but overall, biological agents offer new hope and better treatment prospects for people with rheumatism arthritis.
